AIM ImmunoTech Inc. (AIM)
NYSE American · Manufacturing · Biological products, (no diagnostic substances)
$0.1901−$0.0132 (−6.49%) on the dayAs of the close; data may be delayed.
AIM price, last 12 months
Key stats
- Previous close
- $0.2033
- Open
- $0.2010
- Day range
- $0.1874 – $0.2022
- 52-week range
- $0.1874 – $2.94
- Volume
- 1.9M
- Avg volume (20 days)
- 12.6M
- Market cap
- $7.4M
Performance
1W−8.4%
1M−24.0%
3M−39.1%
6M−72.5%
YTD−83.2%
1Y−93.1%
vs S&P 500, 1Y−109.9 pts
Technicals and fundamentals
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NYSE American
- Market cap
- $7.4M